The Emergence of Antibody Fragments and Derivatives
Antibody fragments have distinct advantages over antibodies, and with
both commercially viable fragments in the marketplace and numerous
candidates in various stages of development, they look set to offer
a credible therapeutic alternative to full-length mAbs.
By Gurdeep Singh Athwal at Novozymes BioPharma UK (July 2009)
Keywords: antibody fragments, Kohler, Milstein, monoclonal, mAbs, technologies, production, development, growth